1. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation 
Ya-Zhen Qin, Yao Chen, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Xiao-Su Zhao, Kai-Yan Liu, Xiao-Jun Huang 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 1, Pages (January 2018)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 CIR (A), DFS (B), and OS (C) for the whole cohort.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Sequential TLS-ERG transcript levels at diagnosis, pre-HSCT, and post-HSCT in 14 patients. The number in the boxes represent TLS-ERG transcript levels at diagnosis. Arrows represent interventions; 8 patients received preemptive DLI, and 1 patient received IFN-α. Dx, at diagnosis; UKN, unknown; HR, hematologic relapse; EMR, extramedullary relapse; NRM, nonrelapse mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Dynamics of TLS-ERG transcript levels after treatment with modified DLI (7 patients; solid line) or IFN-α (1 patient; dashed line).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions